Apogee Therapeutics Files Preliminary Proxy for AbbVie Acquisition Vote
APGE has more than doubled off its 52-week low of $34.34.
Summary
Apogee Therapeutics filed a preliminary proxy statement detailing the terms of its acquisition by AbbVie for $135.11 per share in cash, seeking shareholder approval for the deal and related executive compensation.
Key Events · M&A and Partnerships · APGE
-
Acquisition Details Confirmed
Apogee Therapeutics is set to be acquired by AbbVie Inc. for $135.11 per share in cash. This price represents a 53% premium to Apogee's closing share price on June 17, 2026, and a 63% premium to the 30-day volume-weighted average trading price prior to that date. The merger is expected to close by the third quarter of 2026.
-
Shareholder Vote Scheduled
A special meeting will be held virtually on a placeholder date in 2026 for stockholders to vote on the merger proposal, an advisory proposal on executive compensation, and a proposal to adjourn the meeting if necessary. The board unanimously recommends voting 'FOR' all proposals.
-
Strong Shareholder Support
Key stockholders, including Fairmount Healthcare Fund II, L.P. and Venrock Healthcare Capital Partners III, L.P., who collectively own all outstanding non-voting common stock and a portion of voting common stock, have agreed to vote their shares in favor of the merger. Non-voting common stockholders have already provided written consent.
-
Financial Advisor Fairness Opinions
Goldman Sachs & Co. LLC and Jefferies LLC each delivered fairness opinions to Apogee's board, stating that the $135.11 per share merger consideration is fair from a financial point of view to the company's shareholders.
Analysis · APGE · Life Sciences
This preliminary proxy statement provides comprehensive details for shareholders to vote on the previously announced acquisition of Apogee Therapeutics by AbbVie Inc. for $135.11 per share in cash. While the merger agreement was announced on June 22, 2026, this filing is critical for the formal shareholder approval process, outlining the board's unanimous recommendation, fairness opinions from financial advisors, and significant merger-related compensation for executives. The substantial premium offered to shareholders, coupled with strong insider support, indicates a high likelihood of deal completion, leading to the company's delisting.
At the time of this filing, APGE was trading at $133.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $34.34 to $133.85. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.